Robinson, D.; Humbert, M.; Buhl, R. et al.
Revisiting Type 2-high and Type 2-low airway inflammation in asthma: current knowledge and therapeutic implicationsCLINICAL AND EXPERIMENTAL ALLERGY. Bd. 47. H. 2. 2017 S. 161-175
Bousquet, J.; Farrell, J.; Crooks, G. et al.
Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B3: Area 5) (vol 6, 29, 2016)CLINICAL AND TRANSLATIONAL ALLERGY. Bd. 7. 2017
Buhl, Roland; Humbert, Marc; Bjermer, Leif et al.
Severe eosinophilic asthma: a roadmap to consensusEUROPEAN RESPIRATORY JOURNAL. Bd. 49. H. 5. 2017
Sagheb, Keyvan; Manz, Asina; Albrich, Stefan B. et al.
Supraclavicular Metastases from Distant Primary Solid Tumours: A Retrospective Study of 41 YearsJOURNAL OF MAXILLOFACIAL & ORAL SURGERY. Bd. 16. H. 2. 2017 S. 152-157
Stadler, Nicole; Hasibeder, Astrid; Lopez, Pamela Aranda et al.
The Bruton tyrosine kinase inhibitor ibrutinib abrogates triggering receptor on myeloid cells 1-mediated neutrophil activationHAEMATOLOGICA. Bd. 102. H. 5. 2017 S. E191-E194
Lommatzsch, M.; Buhl, R.
The new 2017 GINA guidelines. What is new?PNEUMOLOGE. Bd. 14. H. 5. 2017 S. 303-308
Lopez, Pamela Aranda; Denny, Mark; Hartmann, Ann-Kathrin et al.
Transcutaneous immunization with a novel imiquimod nanoemulsion induces superior T cell responses and virus protectionJOURNAL OF DERMATOLOGICAL SCIENCE. Bd. 87. H. 3. 2017 S. 252-259
Neuenhahn, M.; Albrecht, J.; Odendahl, M. et al.
Transfer of minimally manipulated CMV-specific T cells from stem cell or third-party donors to treat CMV infection after allo-HSCTLEUKEMIA. Bd. 31. H. 10. 2017 S. 2161-2171
Pal, Marina; Schwab, Lisa; Yermakova, Anastasiya et al.
Tumor-priming converts NK cells to memory-like NK cellsONCOIMMUNOLOGY. Bd. 6. H. 6. 2017
Ferreri, Andres J. M.; Cwynarski, Kate; Pulczynski, Elisa et al.
Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trialLANCET HAEMATOLOGY. Bd. 4. H. 11. 2017 S. E510-E523